# A Phase 1/2A Study of LAM561 in Adult Patients With Advanced Solid Tumours

> **NCT01792310** · PHASE1,PHASE2 · COMPLETED · sponsor: **Laminar Pharmaceuticals** · enrollment: 54 (actual)

## Conditions studied

- Glioma
- Other Solid Tumours

## Interventions

- **DRUG:** LAM561

## Key facts

- **NCT ID:** NCT01792310
- **Lead sponsor:** Laminar Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2023-02-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01792310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01792310, "A Phase 1/2A Study of LAM561 in Adult Patients With Advanced Solid Tumours". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01792310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*